Filter By Category
Archives
Share on -
DEUPSILOCIN
Generic Name: DEUPSILOCIN
ABSTRACT -
Deupsilocin is a deuterated psilocin-related API name. The structure above is a regenerated high-resolution bond-line chemical image. Rendered formula: C12H16N2O; rendered molecular weight: 207.29 g/mol. Structure basis: deuterated psilocin-like scaffold; exact API isotope pattern not independently confirmed. Confidence category: medium/provisional.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, clinical-trial protocol, and specialist medical supervision.
DOSAGE -
- Dose and route depend on indication, formulation, patient factors, regulatory status, and local labeling.
- Use only the approved product label or validated clinical-development protocol for dosing decisions.
- Adjust, avoid, or monitor carefully where organ impairment, interactions, pregnancy, lactation, or toxicity risk require review.
- Do not use this structured monograph as a substitute for official prescribing information.
SIDE EEFECTS -
Possible side effects and safety concerns include:
- Common reactions may include gastrointestinal symptoms, headache, dizziness, fatigue, rash, or drug-class-specific effects.
- Depending on the API, hepatic, renal, cardiovascular, hematologic, neurologic, endocrine, or dermatologic toxicity may occur.
- Interaction-driven toxicity and overdose effects are possible.
- Monitor according to the current approved label or clinical protocol.
ALLERGIC REACTIONS -
Hypersensitivity to deupsilocin or related compounds/products may occur. Symptoms may include:
- Immediate urticaria, itching, flushing, or generalized rash
- Facial, lip, tongue, or throat swelling
- Wheezing, chest tightness, or breathing difficulty
- Dizziness, fainting, severe hypotension, or collapse
- Anaphylaxis, although uncommon, requires emergency medical treatment
Important: Patients who develop an allergic reaction to deupsilocin should seek immediate medical attention and inform future healthcare providers of the allergy.
DRUG INTERACTIONS-
Deupsilocin may interact with medicines, biologics, supplements, vaccines, or medical conditions. Caution is needed with:
- Other medicines with overlapping toxicity, CYP or transporter effects, CNS depression, QT effects, bleeding risk, immune effects, or organ toxicity may alter safety or efficacy.
- Strong enzyme inhibitors or inducers may change exposure for susceptible small-molecule APIs.
- Biologics, vaccines, immunosuppressants, anticoagulants, chemotherapy, or corticosteroids require specialist review where relevant.
- Patients should report all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements.
PREAUTONS–
- Verify API identity, exact salt/ester/isomer/deuteration pattern, route, formulation, indication, strength, and local regulatory status before use.
- Review renal, hepatic, cardiac, neurologic, hematologic, immune, pregnancy, lactation, pediatric, and geriatric considerations as applicable.
- Use validated quality records for manufacturing, compounding, labeling, or release testing.
- The bond-line image must be interpreted together with the structure-basis note and quality report.
WARNINGS –
- The image is a bond-line chemical drawing but the report flags whether it is exact, parent-scaffold, representative, or proxy; do not treat proxy images as complete API identity records.
- Seek urgent care for breathing difficulty, facial swelling, severe rash, chest pain, fainting, severe fever, seizures, jaundice, confusion, or collapse.
- This document is not a substitute for the approved label, protocol, certificate of analysis, or specialist medical judgment.
- Keep out of reach of children.
Share on -
. Developed by